Charles River Laboratories (NYSE: CRL) posted Q2 2026 revenue of $1.00 billion and non-GAAP EPS of $3.02, then raised full-year guidance on strengthening DSA demand and Manufacturing outperformance, even as GAAP results absorbed a one-time loss from its CDMO and Cell Solutions divestiture.
Eli Lilly Q2 2026 earnings rose 48% to $23.0 billion, driven by Mounjaro and Zepbound demand, as the company raised full-year revenue and EPS guidance and advanced its obesity, oncology, and immunology pipeline through regulatory wins and four completed acquisitions.
Biocon Limited posted a 10% YoY rise in Q1 FY27 consolidated revenue to Rs 4,336 crore, powered by 17% biopharma growth, a 349% jump in net profit, and continued biosimilar launches across the US and Canada.
Pfizer Q2 2026 Earnings report $15.03B in revenue, fueled by an 18% operational surge in non-COVID biopharmaceuticals including Padcev and Vyndaqel.
Merck posted $16.6 billion in Q2 2026 sales as LIPFENDRA won FDA approval and KEYTRUDA QLEX gained traction, even as a Terns acquisition charge drove a GAAP loss.
AbbVie’s Q2 2026 earnings show $16.99 billion in net revenues (+10.2%), record Skyrizi and Rinvoq growth, a $10.9 billion Apogee Therapeutics acquisition, and updated full-year adjusted EPS guidance.
Sun Pharma’s Q1FY27 results show consolidated sales up 10.1% to Rs. 151,836 million, net profit at Rs. 28,948 million, and 16% growth in India Formulations, as the Organon acquisition clears a key shareholder milestone ahead of an early-2027 close.
IQVIA Q2 2026 results show revenue up 8.7% to $4.368 billion, Adjusted EPS of $3.15, and a raised full-year 2026 outlook, driven by record R&D Solutions bookings and accelerating Commercial Solutions growth.
GSK’s Q2 2026 results show core operating profit up 7% to £2.8 billion, driven by Specialty Medicines and Vaccines, alongside plans for 20+ Phase III trial starts and the $10.6bn Nuvalent acquisition.
AstraZeneca’s H1 2026 results show Total Revenue climbing 9% to $30,672 million and Core EPS up 12% to $5.21, powered by Oncology and Rare Disease growth, 30 new regulatory approvals, and fresh licensing deals for Zegfrovy and TQC3721 — as the company reaffirms its $80 billion 2030 revenue ambition.
